Merck, Pfizer make a late — very late — arrival at the SGLT2 party for diabetes
Merck and Pfizer have landed an FDA approval to start marketing ertugliflozin, marking a late arrival for a therapy that will now go toe-to-toe with some deeply entrenched rivals in the SGLT2 niche.
The FDA noted the approval on its site, hitting the green light for the single therapy as well as combinations with Merck’s Januvia or metformin, the standard therapy for diabetes. Curiously, though, the companies have yet to put out a release marking the occasion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.